Summit Therapeutics Says Partner Akeso Receives Third China NMPA Approval For Ivonescimab, Covering First-Line Advanced Squamous NSCLC With Chemotherapy
Share
Why It Matters
Summit's partner company Akeso got approval in China to sell a cancer medicine for a specific type of lung cancer. This is good news because it shows the medicine is working and the company can make money from it in a big market.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.